How do patients choose between active surveillance, radical prostatectomy, and radiotherapy? The effect of a preference-sensitive decision aid on treatment decision making for localized prostate cancer

Abstract Purpose To determine the effect of a decision aid (DA) on treatment preferences and to investigate which patient preferences are important for final treatment preferences. We also determined if the patient׳s treatment decision was influenced by the urologist׳s treatment preference. Patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Urologic oncology 2017-02, Vol.35 (2), p.37.e9-37.e17
Hauptverfasser: Lamers, Romy E.D., M.D, Cuypers, Maarten, M.Sc, de Vries, Marieke, Ph.D, van de Poll-Franse, Lonneke V., Ph.D, Ruud Bosch, J.L.H., M.D., Ph.D, Kil, Paul J.M., M.D, Ph.D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 37.e17
container_issue 2
container_start_page 37.e9
container_title Urologic oncology
container_volume 35
creator Lamers, Romy E.D., M.D
Cuypers, Maarten, M.Sc
de Vries, Marieke, Ph.D
van de Poll-Franse, Lonneke V., Ph.D
Ruud Bosch, J.L.H., M.D., Ph.D
Kil, Paul J.M., M.D, Ph.D
description Abstract Purpose To determine the effect of a decision aid (DA) on treatment preferences and to investigate which patient preferences are important for final treatment preferences. We also determined if the patient׳s treatment decision was influenced by the urologist׳s treatment preference. Patients and methods Between August 2014 and July 2015, newly diagnosed patients with low-/intermediate-risk prostate cancer were offered to use a web-based DA after diagnosis. Treatment preferences and patient׳s values were extracted from the DA. Urologists׳ treatment preferences were indicated at the time of inclusion. Results We included 181 patients, of whom 21% preferred active surveillance, 33% radical prostatectomy, 10% brachytherapy, 3% external beam radiotherapy, and 34% did not indicate a specific preferred treatment option after DA use (missing N = 6). Among 67%, treatment preference before DA use did not change after DA use. In men who chose active surveillance after DA use, 97% (37/38) preferred to postpone unnecessary treatment. For radical prostatectomy, 91% (52/57) of the patients valued tumor removal, and for brachytherapy, 88% (15/17) valued incontinence worse than bowel complaints. For 64% (missing N = 21) of the patients, urologists indicated one specific preferred treatment option as most suitable for the patient concerned. Agreement between final treatment decision and urologist׳s preference was lower ( κ = 0.68) than between final treatment decision and preferred treatment after DA use ( κ = 0.82). Conclusion Most patients with prostate cancer chose the treatment in accordance with the post-DA preference and to a lesser extent the urologists preference; implications of this are prospectively investigated in an ongoing study.
doi_str_mv 10.1016/j.urolonc.2016.09.007
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1881269335</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1078143916302757</els_id><sourcerecordid>1881269335</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-54bb4fff763cddb780b700ba9dee73bdc050cd10dfa0e12aaab8a12c976e7c2a3</originalsourceid><addsrcrecordid>eNqFUsFu1DAQjRAVLYVPAPnIoQl2nMTJhaqqgCJV6qHt2ZrYY9bbJF5sZ6vlD_krnO5SJC6cxta8mTfz3mTZO0YLRlnzcV3M3g1uUkWZvgXtCkrFi-yEtYLnZdU1L9ObijZnFe-Os9chrCllVcvYq-y4bHnFqq46yX5duUeiHdlAtDjFQNTKuYCkx_iIOBFQ0W6RhNlv0Q4DTArPiAdtFQxk412IEFFFN-7OCEz6KeXiCj1sdufkboUEjUkA4gyBVIAGPaYmecAp2KfeGpUN1iUuq0kK0SPEMQ3zNzPCg52-E-M8GVxitj9RP7MTtUzl32RHBoaAbw_xNLv_8vnu8iq_vvn67fLiOldVI2JeV31fGWNEw5XWvWhpLyjtodOIgvda0Zoqzag2QJGVANC3wErViQaFKoGfZh_2fRP_jxlDlKMNChdt0M1BsrZlZdNxXidovYeqNGpIu8uNtyP4nWRULi7KtTy4KBcXJe1kcjHVvT9QzP2I-rnqj20JcL4HYFp0a9HLoOwiq7Y-iS21s_-l-PRPBzXYaXH1AXcY1m72U1JRMhlKSeXtckrLJbGG01LUgv8GstHNGA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1881269335</pqid></control><display><type>article</type><title>How do patients choose between active surveillance, radical prostatectomy, and radiotherapy? The effect of a preference-sensitive decision aid on treatment decision making for localized prostate cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Lamers, Romy E.D., M.D ; Cuypers, Maarten, M.Sc ; de Vries, Marieke, Ph.D ; van de Poll-Franse, Lonneke V., Ph.D ; Ruud Bosch, J.L.H., M.D., Ph.D ; Kil, Paul J.M., M.D, Ph.D</creator><creatorcontrib>Lamers, Romy E.D., M.D ; Cuypers, Maarten, M.Sc ; de Vries, Marieke, Ph.D ; van de Poll-Franse, Lonneke V., Ph.D ; Ruud Bosch, J.L.H., M.D., Ph.D ; Kil, Paul J.M., M.D, Ph.D</creatorcontrib><description>Abstract Purpose To determine the effect of a decision aid (DA) on treatment preferences and to investigate which patient preferences are important for final treatment preferences. We also determined if the patient׳s treatment decision was influenced by the urologist׳s treatment preference. Patients and methods Between August 2014 and July 2015, newly diagnosed patients with low-/intermediate-risk prostate cancer were offered to use a web-based DA after diagnosis. Treatment preferences and patient׳s values were extracted from the DA. Urologists׳ treatment preferences were indicated at the time of inclusion. Results We included 181 patients, of whom 21% preferred active surveillance, 33% radical prostatectomy, 10% brachytherapy, 3% external beam radiotherapy, and 34% did not indicate a specific preferred treatment option after DA use (missing N = 6). Among 67%, treatment preference before DA use did not change after DA use. In men who chose active surveillance after DA use, 97% (37/38) preferred to postpone unnecessary treatment. For radical prostatectomy, 91% (52/57) of the patients valued tumor removal, and for brachytherapy, 88% (15/17) valued incontinence worse than bowel complaints. For 64% (missing N = 21) of the patients, urologists indicated one specific preferred treatment option as most suitable for the patient concerned. Agreement between final treatment decision and urologist׳s preference was lower ( κ = 0.68) than between final treatment decision and preferred treatment after DA use ( κ = 0.82). Conclusion Most patients with prostate cancer chose the treatment in accordance with the post-DA preference and to a lesser extent the urologists preference; implications of this are prospectively investigated in an ongoing study.</description><identifier>ISSN: 1078-1439</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2016.09.007</identifier><identifier>PMID: 28341494</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Decision aid ; Decision Making ; Decision Support Techniques ; Humans ; Male ; Middle Aged ; Patient Preference - statistics &amp; numerical data ; Patient preferences ; Prostate cancer ; Prostatectomy - methods ; Prostatic Neoplasms - psychology ; Prostatic Neoplasms - therapy ; Radiotherapy - methods ; Surveys and Questionnaires ; Treatment ; Urology</subject><ispartof>Urologic oncology, 2017-02, Vol.35 (2), p.37.e9-37.e17</ispartof><rights>Elsevier Inc.</rights><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-54bb4fff763cddb780b700ba9dee73bdc050cd10dfa0e12aaab8a12c976e7c2a3</citedby><cites>FETCH-LOGICAL-c467t-54bb4fff763cddb780b700ba9dee73bdc050cd10dfa0e12aaab8a12c976e7c2a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.urolonc.2016.09.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28341494$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lamers, Romy E.D., M.D</creatorcontrib><creatorcontrib>Cuypers, Maarten, M.Sc</creatorcontrib><creatorcontrib>de Vries, Marieke, Ph.D</creatorcontrib><creatorcontrib>van de Poll-Franse, Lonneke V., Ph.D</creatorcontrib><creatorcontrib>Ruud Bosch, J.L.H., M.D., Ph.D</creatorcontrib><creatorcontrib>Kil, Paul J.M., M.D, Ph.D</creatorcontrib><title>How do patients choose between active surveillance, radical prostatectomy, and radiotherapy? The effect of a preference-sensitive decision aid on treatment decision making for localized prostate cancer</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>Abstract Purpose To determine the effect of a decision aid (DA) on treatment preferences and to investigate which patient preferences are important for final treatment preferences. We also determined if the patient׳s treatment decision was influenced by the urologist׳s treatment preference. Patients and methods Between August 2014 and July 2015, newly diagnosed patients with low-/intermediate-risk prostate cancer were offered to use a web-based DA after diagnosis. Treatment preferences and patient׳s values were extracted from the DA. Urologists׳ treatment preferences were indicated at the time of inclusion. Results We included 181 patients, of whom 21% preferred active surveillance, 33% radical prostatectomy, 10% brachytherapy, 3% external beam radiotherapy, and 34% did not indicate a specific preferred treatment option after DA use (missing N = 6). Among 67%, treatment preference before DA use did not change after DA use. In men who chose active surveillance after DA use, 97% (37/38) preferred to postpone unnecessary treatment. For radical prostatectomy, 91% (52/57) of the patients valued tumor removal, and for brachytherapy, 88% (15/17) valued incontinence worse than bowel complaints. For 64% (missing N = 21) of the patients, urologists indicated one specific preferred treatment option as most suitable for the patient concerned. Agreement between final treatment decision and urologist׳s preference was lower ( κ = 0.68) than between final treatment decision and preferred treatment after DA use ( κ = 0.82). Conclusion Most patients with prostate cancer chose the treatment in accordance with the post-DA preference and to a lesser extent the urologists preference; implications of this are prospectively investigated in an ongoing study.</description><subject>Aged</subject><subject>Decision aid</subject><subject>Decision Making</subject><subject>Decision Support Techniques</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patient Preference - statistics &amp; numerical data</subject><subject>Patient preferences</subject><subject>Prostate cancer</subject><subject>Prostatectomy - methods</subject><subject>Prostatic Neoplasms - psychology</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Radiotherapy - methods</subject><subject>Surveys and Questionnaires</subject><subject>Treatment</subject><subject>Urology</subject><issn>1078-1439</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUsFu1DAQjRAVLYVPAPnIoQl2nMTJhaqqgCJV6qHt2ZrYY9bbJF5sZ6vlD_krnO5SJC6cxta8mTfz3mTZO0YLRlnzcV3M3g1uUkWZvgXtCkrFi-yEtYLnZdU1L9ObijZnFe-Os9chrCllVcvYq-y4bHnFqq46yX5duUeiHdlAtDjFQNTKuYCkx_iIOBFQ0W6RhNlv0Q4DTArPiAdtFQxk412IEFFFN-7OCEz6KeXiCj1sdufkboUEjUkA4gyBVIAGPaYmecAp2KfeGpUN1iUuq0kK0SPEMQ3zNzPCg52-E-M8GVxitj9RP7MTtUzl32RHBoaAbw_xNLv_8vnu8iq_vvn67fLiOldVI2JeV31fGWNEw5XWvWhpLyjtodOIgvda0Zoqzag2QJGVANC3wErViQaFKoGfZh_2fRP_jxlDlKMNChdt0M1BsrZlZdNxXidovYeqNGpIu8uNtyP4nWRULi7KtTy4KBcXJe1kcjHVvT9QzP2I-rnqj20JcL4HYFp0a9HLoOwiq7Y-iS21s_-l-PRPBzXYaXH1AXcY1m72U1JRMhlKSeXtckrLJbGG01LUgv8GstHNGA</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Lamers, Romy E.D., M.D</creator><creator>Cuypers, Maarten, M.Sc</creator><creator>de Vries, Marieke, Ph.D</creator><creator>van de Poll-Franse, Lonneke V., Ph.D</creator><creator>Ruud Bosch, J.L.H., M.D., Ph.D</creator><creator>Kil, Paul J.M., M.D, Ph.D</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170201</creationdate><title>How do patients choose between active surveillance, radical prostatectomy, and radiotherapy? The effect of a preference-sensitive decision aid on treatment decision making for localized prostate cancer</title><author>Lamers, Romy E.D., M.D ; Cuypers, Maarten, M.Sc ; de Vries, Marieke, Ph.D ; van de Poll-Franse, Lonneke V., Ph.D ; Ruud Bosch, J.L.H., M.D., Ph.D ; Kil, Paul J.M., M.D, Ph.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-54bb4fff763cddb780b700ba9dee73bdc050cd10dfa0e12aaab8a12c976e7c2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Decision aid</topic><topic>Decision Making</topic><topic>Decision Support Techniques</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patient Preference - statistics &amp; numerical data</topic><topic>Patient preferences</topic><topic>Prostate cancer</topic><topic>Prostatectomy - methods</topic><topic>Prostatic Neoplasms - psychology</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Radiotherapy - methods</topic><topic>Surveys and Questionnaires</topic><topic>Treatment</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lamers, Romy E.D., M.D</creatorcontrib><creatorcontrib>Cuypers, Maarten, M.Sc</creatorcontrib><creatorcontrib>de Vries, Marieke, Ph.D</creatorcontrib><creatorcontrib>van de Poll-Franse, Lonneke V., Ph.D</creatorcontrib><creatorcontrib>Ruud Bosch, J.L.H., M.D., Ph.D</creatorcontrib><creatorcontrib>Kil, Paul J.M., M.D, Ph.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lamers, Romy E.D., M.D</au><au>Cuypers, Maarten, M.Sc</au><au>de Vries, Marieke, Ph.D</au><au>van de Poll-Franse, Lonneke V., Ph.D</au><au>Ruud Bosch, J.L.H., M.D., Ph.D</au><au>Kil, Paul J.M., M.D, Ph.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How do patients choose between active surveillance, radical prostatectomy, and radiotherapy? The effect of a preference-sensitive decision aid on treatment decision making for localized prostate cancer</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2017-02-01</date><risdate>2017</risdate><volume>35</volume><issue>2</issue><spage>37.e9</spage><epage>37.e17</epage><pages>37.e9-37.e17</pages><issn>1078-1439</issn><eissn>1873-2496</eissn><abstract>Abstract Purpose To determine the effect of a decision aid (DA) on treatment preferences and to investigate which patient preferences are important for final treatment preferences. We also determined if the patient׳s treatment decision was influenced by the urologist׳s treatment preference. Patients and methods Between August 2014 and July 2015, newly diagnosed patients with low-/intermediate-risk prostate cancer were offered to use a web-based DA after diagnosis. Treatment preferences and patient׳s values were extracted from the DA. Urologists׳ treatment preferences were indicated at the time of inclusion. Results We included 181 patients, of whom 21% preferred active surveillance, 33% radical prostatectomy, 10% brachytherapy, 3% external beam radiotherapy, and 34% did not indicate a specific preferred treatment option after DA use (missing N = 6). Among 67%, treatment preference before DA use did not change after DA use. In men who chose active surveillance after DA use, 97% (37/38) preferred to postpone unnecessary treatment. For radical prostatectomy, 91% (52/57) of the patients valued tumor removal, and for brachytherapy, 88% (15/17) valued incontinence worse than bowel complaints. For 64% (missing N = 21) of the patients, urologists indicated one specific preferred treatment option as most suitable for the patient concerned. Agreement between final treatment decision and urologist׳s preference was lower ( κ = 0.68) than between final treatment decision and preferred treatment after DA use ( κ = 0.82). Conclusion Most patients with prostate cancer chose the treatment in accordance with the post-DA preference and to a lesser extent the urologists preference; implications of this are prospectively investigated in an ongoing study.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28341494</pmid><doi>10.1016/j.urolonc.2016.09.007</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1078-1439
ispartof Urologic oncology, 2017-02, Vol.35 (2), p.37.e9-37.e17
issn 1078-1439
1873-2496
language eng
recordid cdi_proquest_miscellaneous_1881269335
source MEDLINE; Elsevier ScienceDirect Journals
subjects Aged
Decision aid
Decision Making
Decision Support Techniques
Humans
Male
Middle Aged
Patient Preference - statistics & numerical data
Patient preferences
Prostate cancer
Prostatectomy - methods
Prostatic Neoplasms - psychology
Prostatic Neoplasms - therapy
Radiotherapy - methods
Surveys and Questionnaires
Treatment
Urology
title How do patients choose between active surveillance, radical prostatectomy, and radiotherapy? The effect of a preference-sensitive decision aid on treatment decision making for localized prostate cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T12%3A33%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20do%20patients%20choose%20between%20active%20surveillance,%20radical%20prostatectomy,%20and%20radiotherapy?%20The%20effect%20of%20a%20preference-sensitive%20decision%20aid%20on%20treatment%20decision%20making%20for%20localized%20prostate%20cancer&rft.jtitle=Urologic%20oncology&rft.au=Lamers,%20Romy%20E.D.,%20M.D&rft.date=2017-02-01&rft.volume=35&rft.issue=2&rft.spage=37.e9&rft.epage=37.e17&rft.pages=37.e9-37.e17&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2016.09.007&rft_dat=%3Cproquest_cross%3E1881269335%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1881269335&rft_id=info:pmid/28341494&rft_els_id=1_s2_0_S1078143916302757&rfr_iscdi=true